Comparative Pharmacology
Head-to-head clinical analysis: LYSTEDA versus TRANEXAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LYSTEDA versus TRANEXAMIC ACID.
LYSTEDA vs TRANEXAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis.
Competitive inhibitor of plasminogen activation, blocking the binding of plasminogen to fibrin, thereby preventing fibrinolysis and stabilizing clots.
650 mg orally three times daily (total 3.9 g/day) for up to 5 days during menses.
1 g intravenously every 8 hours for prophylaxis of bleeding in cardiac surgery; for heavy menstrual bleeding: 1.3 g orally three times daily for up to 5 days during menstruation.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1.5–2.5 hours). In patients with renal impairment, half-life is significantly prolonged (up to 20 hours in severe renal impairment).
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateTranexamic acid + Estramustine
"Tranexamic acid may increase the thrombogenic activities of Estramustine."
Clinical Note
moderateTranexamic acid + Tretinoin
"Tranexamic acid may increase the thrombogenic activities of Tretinoin."
Clinical Note
moderateTranexamic acid + Diethylstilbestrol
Terminal elimination half-life approximately 2-11 hours (mean 2 hours in healthy adults; prolonged to 7-15 hours in renal impairment). Clinical context: dosing interval adjustment required in renal insufficiency.
Primarily renal excretion (>95% unchanged drug via glomerular filtration). Less than 5% is metabolized (mainly acylated derivative).
Primarily renal excretion as unchanged drug (95% within 24 hours) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antifibrinolytic
Antifibrinolytic
"Tranexamic acid may increase the thrombogenic activities of Diethylstilbestrol."